With the drive in oncology to develop molecules targeting the immune system, there is a need for reliable and well-characterized preclinical models.
Orthotopic modeling is becoming increasingly employed in preclinical development as it is posited to have improved clinical translatability compared to subcutaneous implantation.
We developed a luciferase enabled A20 murine B cell lymphoma cell line (A20-luc) to better understand the utility of subcutaneous and orthotopic modeling of A20 in preclinical oncology drug development.
A panel of checkpoint inhibitors and costimulatory agonists were assessed for anti-tumor response both in the subcutaneous and systemic disease settings.
Investigation of infiltration of lymphoid and myeloid cell subsets in subcutaneous A20 tumors were evaluated. Knowledge of this immune composition can help guide rational monotherapy and combination strategies.